nach oben

Erschienen in:

10.01.2020 | Original Paper

Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial

verfasst von: Mariusz Tomaniak, Ply Chichareon, Dominika Klimczak-Tomaniak, Kuniaki Takahashi, Norihiro Kogame, Rodrigo Modolo, Rutao Wang, Masafumi Ono, Hironori Hara, Chao Gao, Hideyuki Kawashima, Tessa Rademaker-Havinga, Scot Garg, Nick Curzen, Michael Haude, Janusz Kochman, Tommaso Gori, Gilles Montalescot, Dominick J. Angiolillo, Davide Capodanno, Robert F. Storey, Christian Hamm, Pascal Vranckx, Marco Valgimigli, Stephan Windecker, Yoshinobu Onuma, Patrick W. Serruys, Richard Anderson

Erschienen in: Clinical Research in Cardiology | Ausgabe 7/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Impaired renal function (IRF) is associated with increased risks of both ischemic and bleeding events. Ticagrelor has been shown to provide greater absolute reduction in ischemic risk following acute coronary syndrome (ACS) in those with versus without IRF.

Methods

A pre-specified sub-analysis of the randomized GLOBAL LEADERS trial (n = 15,991) comparing the experimental strategy of 23-month ticagrelor monotherapy (after 1-month ticagrelor and aspirin dual anti-platelet therapy [DAPT]) with 12-month DAPT followed by 12-month aspirin after percutaneous coronary intervention (PCI) in ACS and stable coronary artery disease (CAD) patients stratified according to IRF (glomerular filtration rate < 60 ml/min/1.73 m²).

Results

At 2 years, patients with IRF (n = 2171) had a higher rate of the primary endpoint (all-cause mortality or centrally adjudicated, new Q-wave myocardial infarction [MI](hazard ratio [HR] 1.64, 95% confidence interval [CI] 1.35–1.98, p_adj = 0.001), all-cause death, site-reported MI, all revascularization and BARC 3 or 5 type bleeding, compared with patients without IRF. Among patients with IRF, there were similar rates of the primary endpoint (HR 0.82, 95% CI 0.61–1.11, p = 0.192, p_int = 0.680) and BARC 3 or 5 type bleeding (HR 1.10, 95% CI 0.71–1.71, p = 0.656, p_int = 0.506) in the experimental versus the reference group. No significant interactions were seen between IRF and treatment effect for any of the secondary outcome variables. Among ACS patients with IRF, there were no between-group differences in the rates of the primary endpoint or BARC 3 or 5 type bleeding; however, the rates of the patient-oriented composite endpoint (POCE) of all-cause death, any stroke, MI, or revascularization (p_int = 0.028) and net adverse clinical events (POCE and BARC 3 or 5 type bleeding) (p_int = 0.045), were lower in the experimental versus the reference group. No treatment effects were found in stable CAD patients categorized according to presence of IRF.

Conclusions

IRF negatively impacted long-term prognosis after PCI. There were no differential treatment effects found with regard to all-cause death or new Q-wave MI after PCI in patients with IRF treated with ticagrelor monotherapy.

Clinical trial registration

The trial has been registered with ClinicalTrials.gov, number NCT01813435.

Graphic abstract

Nur mit Berechtigung zugänglich

Dumaine RL, Montalescot G, Steg PG, Ohman EM, Eagle K, Bhatt DL, Investigators RR (2009) Renal function, atherothrombosis extent, and outcomes in high-risk patients. Am Heart J 158(1):141–148.e141. https://doi.org/10.1016/j.ahj.2009.05.011 CrossRefPubMed

Capodanno D, Angiolillo DJ (2012) Antithrombotic therapy in patients with chronic kidney disease. Circulation 125(21):2649–2661. https://doi.org/10.1161/CIRCULATIONAHA.111.084996 CrossRefPubMed

Bonello L, Angiolillo DJ, Aradi D, Sibbing D (2018) P2Y12-ADP receptor blockade in chronic kidney disease patients with acute coronary syndromes. Circulation 138(15):1582–1596. https://doi.org/10.1161/CIRCULATIONAHA.118.032078 CrossRefPubMed

Lee SY, Hong MK, Shin DH, Kim JS, Kim BK, Ko YG, Choi D, Jang Y, Kim HS, Valgimigli M, Palmerini T, Stone GW (2017) Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors. Clin Res Cardiol 106(3):165–173. https://doi.org/10.1007/s00392-016-1035-4 CrossRefPubMed

Weidner K, Behnes M, Schupp T, Rusnak J, Reiser L, Taton G, Reichelt T, Ellguth D, Engelke N, Bollow A, El-Battrawy I, Ansari U, Hoppner J, Nienaber CA, Mashayekhi K, Weiss C, Akin M, Borggrefe M, Akin I (2019) Prognostic impact of chronic kidney disease and renal replacement therapy in ventricular tachyarrhythmias and aborted cardiac arrest. Clin Res Cardiol 108(6):669–682. https://doi.org/10.1007/s00392-018-1396-y CrossRefPubMed

Marx N, Noels H, Jankowski J, Floege J, Fliser D, Bohm M (2018) Mechanisms of cardiovascular complications in chronic kidney disease: research focus of the transregional research consortium SFB TRR219 of the University Hospital Aachen (RWTH) and the Saarland University. Clin Res Cardiol 107(Suppl 2):120–126. https://doi.org/10.1007/s00392-018-1260-0 CrossRefPubMed

Lutz J, Menke J, Sollinger D, Schinzel H, Thurmel K (2014) Haemostasis in chronic kidney disease. Nephrol Dial Transplant 29(1):29–40. https://doi.org/10.1093/ndt/gft209 CrossRefPubMed

Franchi F, Rollini F, Angiolillo DJ (2015) Defining the link between chronic kidney disease, high platelet reactivity, and clinical outcomes in clopidogrel-treated patients undergoing percutaneous coronary intervention. Circ Cardiovasc Interv 8(6):e002760. https://doi.org/10.1161/CIRCINTERVENTIONS.115.002760 CrossRefPubMed

James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, Harrington RA, Horrow J, Katus H, Keltai M, Lewis BS, Parikh K, Storey RF, Szummer K, Wojdyla D, Wallentin L (2010) Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the platelet inhibition and patient outcomes (PLATO) trial. Circulation 122(11):1056–1067. https://doi.org/10.1161/CIRCULATIONAHA.109.933796 CrossRefPubMed

10.

Capodanno D, Mehran R, Valgimigli M, Baber U, Windecker S, Vranckx P, Dangas G, Rollini F, Kimura T, Collet JP, Gibson CM, Steg PG, Lopes RD, Gwon HC, Storey RF, Franchi F, Bhatt DL, Serruys PW, Angiolillo DJ (2018) Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. Nat Rev Cardiol 15(8):480–496. https://doi.org/10.1038/s41569-018-0049-1 CrossRefPubMed

11.

Vranckx P, Valgimigli M, Juni P, Hamm C, Steg PG, Heg D, van Es GA, McFadden EP, Onuma Y, van Meijeren C, Chichareon P, Benit E, Mollmann H, Janssens L, Ferrario M, Moschovitis A, Zurakowski A, Dominici M, Van Geuns RJ, Huber K, Slagboom T, Serruys PW, Windecker S, Investigators GL (2018) Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet. https://doi.org/10.1016/S0140-6736(18)31858-0 CrossRefPubMed

12.

Stevens PE, Levin A, Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group M (2013) Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 158(11):825–830. https://doi.org/10.7326/0003-4819-158-11-201306040-00007 CrossRefPubMed

13.

Vranckx P, Valgimigli M, Windecker S, Steg PG, Hamm C, Juni P, Garcia-Garcia HM, van Es GA, Serruys PW (2016) Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial. EuroIntervention 12(10):1239–1245. https://doi.org/10.4244/EIJY15M11_07 CrossRefPubMed

14.

Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, Lenk K, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice M-C, di Mario C, Davies S, van Geuns R-J, Eerdmans P, van Es G-A, Meier B, Jüni P (2008) Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. The Lancet 372(9644):1163–1173. https://doi.org/10.1016/s0140-6736(08)61244-1 CrossRef

15.

Stevens LA, Coresh J, Greene T, Levey AS (2006) Assessing kidney function—measured and estimated glomerular filtration rate. N Engl J Med 354(23):2473–2483. https://doi.org/10.1056/NEJMra054415 CrossRefPubMed

16.

Prineas R, Crow RS, Zhang Z (2010) The Minnesota code manual of electrocardiographic findings. Springer, LondonCrossRef

17.

Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H (2011) Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation 123(23):2736–2747. https://doi.org/10.1161/CIRCULATIONAHA.110.009449 CrossRefPubMed

18.

Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW, Academic Research C (2007) Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115(17):2344–2351. https://doi.org/10.1161/CIRCULATIONAHA.106.685313 CrossRefPubMed

19.

Garcia-Garcia HM, McFadden EP, Farb A, Mehran R, Stone GW, Spertus J, Onuma Y, Morel MA, van Es GA, Zuckerman B, Fearon WF, Taggart D, Kappetein AP, Krucoff MW, Vranckx P, Windecker S, Cutlip D, Serruys PW, Academic Research C (2018) Standardized end point definitions for coronary intervention trials: the academic research consortium-2 consensus document. Eur Heart J 39(23):2192–2207. https://doi.org/10.1093/eurheartj/ehy223 CrossRefPubMed

20.

Tomaniak M, Chichareon P, Onuma Y, Deliargyris EN, Takahashi K, Kogame N, Modolo R, Chang CC, Rademaker-Havinga T, Storey RF, Dangas GD, Bhatt DL, Angiolillo DJ, Hamm C, Valgimigli M, Windecker S, Steg PG, Vranckx P, Serruys PW, Investigators tGLT (2019) Benefit and risks of aspirin on top of ticagrelor in acute coronary syndromes: a post hoc analysis of the randomized GLOBAL LEADERS trial. JAMA Cardiol. https://doi.org/10.1001/jamacardio.2019.2255 CrossRefPubMedPubMedCentral

21.

Valgimigli M, Frigoli E, Leonardi S, Rothenbuhler M, Gagnor A, Calabro P, Garducci S, Rubartelli P, Briguori C, Ando G, Repetto A, Limbruno U, Garbo R, Sganzerla P, Russo F, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G, Presbitero P, Santarelli A, Sardella G, Varbella F, Tresoldi S, de Cesare N, Rigattieri S, Zingarelli A, Tosi P, t’ van Hof A, Boccuzzi G, Omerovic E, Sabate M, Heg D, Juni P, Vranckx P, Investigators M (2015) Bivalirudin or unfractionated heparin in acute coronary syndromes. N Engl J Med 373(11):997–1009. https://doi.org/10.1056/NEJMoa1507854 CrossRefPubMed

22.

Serruys PW, Takahashi K, Chichareon P, Kogame N, Tomaniak M, Modolo R, Chang CC, Komiyama H, Soliman O, Wykrzykowska JJ, de Winter RJ, Ferrario M, Dominici M, Buszman P, Bolognese L, Tumscitz C, Benit E, Stoll HP, Hamm C, Steg PG, Onuma Y, Juni P, Windecker S, Vranckx P, Colombo A, Valgimigli M (2019) Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the global leaders trial. Eur Heart J 40(31):2595–2604. https://doi.org/10.1093/eurheartj/ehz453 CrossRefPubMed

23.

Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim HS, Kimura T, Konishi A, Laschinger J, Leon MB, Magee PFA, Mitsutake Y, Mylotte D, Pocock S, Price MJ, Rao SV, Spitzer E, Stockbridge N, Valgimigli M, Varenne O, Windhoevel U, Yeh RW, Krucoff MW, Morice MC (2019) Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the academic research consortium for high bleeding risk. Eur Heart J 40(31):2632–2653. https://doi.org/10.1093/eurheartj/ehz372 CrossRefPubMedPubMedCentral

24.

Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM (2007) Statistics in medicine—reporting of subgroup analyses in clinical trials. N Engl J Med 357(21):2189–2194. https://doi.org/10.1056/NEJMsr077003 CrossRefPubMed

25.

Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Investigators P, Freij A, Thorsen M (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361(11):1045–1057. https://doi.org/10.1056/NEJMoa0904327 CrossRefPubMed

26.

Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS, Committee P-TS, Investigators (2015) Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 372(19):1791–1800. https://doi.org/10.1056/NEJMoa1500857 CrossRefPubMed

27.

Wolff G, Lin Y, Quade J, Bader S, Kosejian L, Brockmeyer M, Karathanos A, Parco C, Krieger T, Heinen Y, Perings S, Albert A, Icks A, Kelm M, Schulze V (2019) Validation of national cardiovascular data registry risk models for mortality, bleeding and acute kidney injury in interventional cardiology at a German heart center. Clin Res Cardiol. https://doi.org/10.1007/s00392-019-01506-x CrossRefPubMed

28.

Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM, Investigators T-T (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357(20):2001–2015. https://doi.org/10.1056/NEJMoa0706482 CrossRefPubMed

29.

Bonello L, Laine M, Lemesle G, Puymirat E, Dabry T, Thuny F, Paganelli F, Aradi D, Frere C, Burtey S, Sibbing D, Mancini J (2018) Meta-analysis of potent P2Y12-ADP receptor antagonist therapy compared to clopidogrel therapy in acute coronary syndrome patients with chronic kidney disease. Thromb Haemost 118(10):1839–1846. https://doi.org/10.1055/s-0038-1669426 CrossRefPubMed

30.

Schupke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wohrle J, Richardt G, Liebetrau C, Witzenbichler B, Antoniucci D, Akin I, Bott-Flugel L, Fischer M, Landmesser U, Katus HA, Sibbing D, Seyfarth M, Janisch M, Boncompagni D, Hilz R, Rottbauer W, Okrojek R, Mollmann H, Hochholzer W, Migliorini A, Cassese S, Mollo P, Xhepa E, Kufner S, Strehle A, Leggewie S, Allali A, Ndrepepa G, Schuhlen H, Angiolillo DJ, Hamm CW, Hapfelmeier A, Tolg R, Trenk D, Schunkert H, Laugwitz KL, Kastrati A, Investigators I-RT (2019) Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med. https://doi.org/10.1056/NEJMoa1908973 CrossRefPubMed

31.

Qaderdan K, Ishak M, Heestermans AA, de Vrey E, Jukema JW, Voskuil M, de Boer MJ, van’t Hof AW, Groenemeijer BE, Vos GJ, Janssen PW, Bergmeijer TO, Kelder JC, Deneer VH, ten Berg JM (2015) Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: optimization of antiplatelet treatment in patients 70 years and older—rationale and design of the POPular AGE study. Am Heart J 170(5):981–985.e981. https://doi.org/10.1016/j.ahj.2015.07.030 CrossRefPubMed

32.

Montalescot G, Silvain J (2010) Ticagrelor in the renal dysfunction subgroup: subjugated or substantiated? Circulation 122(11):1049–1052. https://doi.org/10.1161/CIRCULATIONAHA.110.974683 CrossRefPubMed

33.

Angiolillo DJ, Bernardo E, Capodanno D, Vivas D, Sabate M, Ferreiro JL, Ueno M, Jimenez-Quevedo P, Alfonso F, Bass TA, Macaya C, Fernandez-Ortiz A (2010) Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J Am Coll Cardiol 55(11):1139–1146. https://doi.org/10.1016/j.jacc.2009.10.043 CrossRefPubMed

34.

Baber U, Mehran R, Kirtane AJ, Gurbel PA, Christodoulidis G, Maehara A, Witzenbichler B, Weisz G, Rinaldi MJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri EL Jr, Xu K, Parise H, Brodie BR, Stuckey TD, Stone GW (2015) Prevalence and impact of high platelet reactivity in chronic kidney disease: results from the assessment of dual antiplatelet therapy with drug-eluting stents registry. Circ Cardiovasc Interv 8(6):e001683. https://doi.org/10.1161/CIRCINTERVENTIONS.115.001683 CrossRefPubMed

35.

Baber U, Dangas G, Cohen DJ, Gibson CM, Mehta SR, Angiolillo DJ, Pocock SJ, Krucoff MW, Kastrati A, Ohman EM, Steg PG, Badimon J, Zafar MU, Chandrasekhar J, Sartori S, Aquino M, Mehran R (2016) Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: rationale and design of the TWILIGHT study. Am Heart J 182:125–134. https://doi.org/10.1016/j.ahj.2016.09.006 CrossRefPubMed

36.

Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, Cha JY, Collier T, Dangas G, Dudek D, Dzavik V, Escaned J, Gil R, Gurbel P, Hamm CW, Henry T, Huber K, Kastrati A, Kaul U, Kornowski R, Krucoff M, Kunadian V, Marx SO, Mehta SR, Moliterno D, Ohman EM, Oldroyd K, Sardella G, Sartori S, Shlofmitz R, Steg PG, Weisz G, Witzenbichler B, Han YL, Pocock S, Gibson CM (2019) Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med. https://doi.org/10.1056/NEJMoa1908419 CrossRefPubMed

37.

Tomaniak M, Storey RF, Serruys PW (2019) Aspirin-free antiplatelet regimens after PCI: when is it best to stop aspirin and who could ultimately benefit? EuroInterv: J EuroPCR Collab Work Group Interv Cardiol Eur Soc Cardiol. https://doi.org/10.4244/EIJY19M10_01 CrossRef

38.

Serruys PW, Tomaniak M, Chichareon P, Modolo R, Kogame N, Takahashi K, Chang CC, Spitzer E, Walsh SJ, Adlam D, Hildick-Smith D, Edes I, van de Harst P, Krackhardt F, Tijssen JGP, Rademaker-Havinga T, Garg S, Steg PG, Hamm C, Juni P, Vranckx P, Onuma Y, Verheugt FWA (2019) Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: insights from the randomized GLOBAL LEADERS trial. EuroInter: J EuroPCR Collab Work Group Interv Cardiol Eur Soc Cardiol. https://doi.org/10.4244/EIJ-D-19-00202 CrossRef

Titel: Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial
verfasst von: Mariusz Tomaniak
Ply Chichareon
Dominika Klimczak-Tomaniak
Kuniaki Takahashi
Norihiro Kogame
Rodrigo Modolo
Rutao Wang
Masafumi Ono
Hironori Hara
Chao Gao
Hideyuki Kawashima
Tessa Rademaker-Havinga
Scot Garg
Nick Curzen
Michael Haude
Janusz Kochman
Tommaso Gori
Gilles Montalescot
Dominick J. Angiolillo
Davide Capodanno
Robert F. Storey
Christian Hamm
Pascal Vranckx
Marco Valgimigli
Stephan Windecker
Yoshinobu Onuma
Patrick W. Serruys
Richard Anderson
Publikationsdatum: 10.01.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Clinical Research in Cardiology / Ausgabe 7/2020
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-019-01586-9

Neu im Fachgebiet Kardiologie

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial

Abstract

Background

Methods

Results

Conclusions

Clinical trial registration

Graphic abstract

Neu im Fachgebiet Kardiologie

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Parodontalbehandlung verbessert Prognose bei Katheterablation

Update Kardiologie

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Clinical trial registration

Graphic abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2020

Early and late risk of ischemic stroke after TAVR as compared to a nationwide background population

Symptomatic arrhythmias after catheter ablation of atrioventricular nodal reentrant tachycardia (AVNRT): results from the German Ablation Registry

Impact of recruitment and retention on all-cause mortality in a large all-comers randomised controlled trial: insights from the GLOBAL LEADERS trial

Validation of the modified Microlife blood pressure monitor in patients with paroxysmal atrial fibrillation

Correction to: One‑year clinical outcomes in patients with renal insuffciency after contemporary PCI: data from a multicenter registry

One-year clinical outcomes in patients with renal insufficiency after contemporary PCI: data from a multicenter registry

Neu im Fachgebiet Kardiologie

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Parodontalbehandlung verbessert Prognose bei Katheterablation

Update Kardiologie